Institute of Experimental and Clinical Therapeutics, Department of Physiology, Health Sciences University Center, University of Guadalajara, Guadalajara, Jalisco, Mexico.
Exp Clin Endocrinol Diabetes. 2020 Aug;128(8):506-511. doi: 10.1055/a-0664-7583. Epub 2018 Aug 27.
To evaluate the effect of dapagliflozin on insulin secretion and insulin sensitivity in patients with prediabetes.
A randomized, double-blind, placebo-controlled clinical trial was carried out in 24 adults diagnosed with prediabetes and without pharmacological treatment. Patients were randomly assigned into two groups of 12 patients each to receive 10 mg of oral dapagliflozin or placebo once a day during 12 weeks. At baseline and at the end of the study, anthropometric and metabolic measurements were evaluated, including the first phase of insulin secretion, total insulin secretion, and insulin sensitivity.
After dapagliflozin administration, there were significant decreases in body weight (80.8±16.3 vs. 77.8±14.9 kg, p=0.019), body mass index (30.3±3.5 vs. 29.2±3.1 kg/m, p=0.023), waist circumference (100.6±13.5 vs. 96.2±11.8 cm, p=0.003), fasting glucose (5.9±0.4 vs. 5.1±0.3 mmol/L, p<0.001) and uric acid (334.3±70.8 vs. 262.9±60.7 mmol/L, p=0.032), with a tendency to increase the insulin sensitivity (1.94±0.72 vs. 2.63±1.04, p=0.064).
Dapagliflozin administration in patients with prediabetes decreased body weight, body mass index, waist circumference, fasting glucose, and uric acid, with a tendency to increase the insulin sensitivity without changes in insulin secretion.
评估达格列净对糖尿病前期患者胰岛素分泌和胰岛素敏感性的影响。
对 24 例未经药物治疗的糖尿病前期患者进行了一项随机、双盲、安慰剂对照的临床试验。患者随机分为两组，每组 12 例，分别接受每日一次 10mg 达格列净或安慰剂治疗 12 周。在基线和研究结束时，评估了人体测量和代谢测量结果，包括胰岛素第一时相分泌、总胰岛素分泌和胰岛素敏感性。
达格列净给药后，体重（80.8±16.3 与 77.8±14.9kg，p=0.019）、体重指数（30.3±3.5 与 29.2±3.1kg/m，p=0.023）、腰围（100.6±13.5 与 96.2±11.8cm，p=0.003）、空腹血糖（5.9±0.4 与 5.1±0.3mmol/L，p<0.001）和尿酸（334.3±70.8 与 262.9±60.7mmol/L，p=0.032）均显著降低，胰岛素敏感性呈升高趋势（1.94±0.72 与 2.63±1.04，p=0.064）。
达格列净可降低糖尿病前期患者的体重、体重指数、腰围、空腹血糖和尿酸，且胰岛素敏感性呈升高趋势，但对胰岛素分泌无影响。
